Live Breaking News & Updates on Astrazeneca Oxford Vaccine
Stay updated with breaking news from Astrazeneca oxford vaccine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Last Updated: COVID-19: Canada Extends Expiry Date For Thousands Of AstraZeneca Vaccines By 1 Month Amid the COVID-19 pandemic, Ontario on Saturday received permission from Health Canada to extend the expiry of some doses of the AstraZeneca-Oxford vaccine. AP As the world continues to battle against the COVID-19 pandemic, Ontario on Saturday received permission from Health Canada to extend the expiry of some doses of the AstraZeneca-Oxford vaccine, saving thousands of shots from potentially going to waste. A spokesperson for Health Minister Christine Elliott said the change means doses with an original expiry of May 31 can now be used until July 1. ....
India has 26 cases of blood clotting after Covishield vaccination: HealthMin Govt committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases were reported to have potential thromboembolic events. No such events were reported after administration of Covaxin vaccine BusinessToday.In | May 17, 2021 | Updated 15:59 IST Covishield continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections, says the health ministry Bleeding and clotting cases after the COVID-19 vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the national AEFI (adverse event following immunisation) committee to the health ministry has said. Covishield continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India, ....
Health Ministry issues advisory of potential thromboembolic incidents Adverse Event Following Immunisation (AEFI) data in India showed that there is a minuscule but definitive risk of thromboembolic events after the AstraZeneca-Oxford vaccine (Covishield in India). A statement issued by the Health Ministry on Monday noted that the reporting rate of these events in India is around 0.61/million doses, which is much lower than the four cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses. There were no potential thromboembolic events reported following administration of Covaxin vaccine. Bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI to the Health Ministry noted. ....
One Covishield Vaccine Dose Cuts Covid-19 Death Risk By 80%, Claims Study indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.